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Type 2 diabetes mellitus (T2DM) is emerging as a metabolic epidemic worldwide. Pathologically, dysregulation of many biological
pathways precedes hyperglycemia and the clinical diagnosis of T2DM. Changing trajectories along the process of T2DM de-
velopment necessitates frequent measurement of biomarkers for early identiﬁcation of at-risk individuals and successful pre-
vention. Increase in circulating inﬂammatory adipokines has been suggested as predictive of T2DM. Human saliva is an easily
accessible biospecimen amenable for painless frequent collection and possesses nearly 50% of serum proteome. In this study, we
measured the adipokines resistin, visfatin, TNF-α, and ghrelin as markers for T2DM in unstimulated whole saliva (UWS) using
speciﬁc assay kits. Resistin and visfatin concentrations were signiﬁcantly higher in T2DM saliva. Although the concentration of
acylated or unacylated ghrelin was lower in diabetic saliva, the decrease was not signiﬁcant. Since resistin and visfatin are
biomarkers integral to T2DM pathology, their salivary assessments may receive clinical acceptance.
1. Introduction
)e World Health Organization estimated that globally 422
million adults were living with diabetes in 2014 [1]. Type 2
diabetes mellitus (adult-onset/noninsulin-dependent di-
abetes: T2DM) accounts for 90–95% of all diabetes [2]. )e
disease develops insidiously through periods of increased
insulin secretion, insulin resistance, impaired glucose tol-
erance, and β-cell dysfunction [3]. Consistently, the most
acceptable markers for T2DM diagnosis are based on
measurements of blood glucose and glycosylated hemo-
globin c (HbA1c), an indicator of average glycemic control
[4]. However, research elucidating the disease pathogenesis
suggests that multiple mechanisms including chronic in-
ﬂammation, obesity, lipotoxicity, and oxidative stress con-
tribute to the glucose dysregulation in T2DM [5, 6]. Hence,
several hypothesis-based nonglycemic biomarkers have been
assessed as risk factors for diabetes [7, 8].
Adipokines are polypeptides secreted by adipocytes,
inﬂammatory cells, and other cells. )ey regulate multiple
physiological functions including energy balance, insulin
sensitization, appetite regulation, and inﬂammatory re-
sponse [9]. It has been suggested that activation of the
adipokine resistin in the islet cells of the pancreas inhibits
cell surface glucose transporters and thereby insulin sig-
naling [10, 11]. Visfatin, also known as pre-B-cell colony-
enhancing factor (PBEF), has been described as an adipokine
with a potential glucose-lowering eﬀect due to its nicotinamide
phosphoribosyltransferase (NAMPT) activity [10, 12, 13].
Ghrelin, originally identiﬁed as a growth hormone secreta-
gogue with orexigenic and lipogenic eﬀects, has also been
shown to play signiﬁcant roles in glucose regulation. While
acylated ghrelin has been shown to exert hyperglycemic eﬀects
leading to insulin resistance, the unacylated ghrelin counters
hyperglycemia and enhances insulin sensitivity [14, 15]. Bio-
marker studies showed that the circulating levels of resistin
and visfatin are upregulated in T2DM [13, 16–18]. On the
other hand, the plasma concentration of acylated ghrelin has
been shown to be lower in T2DM individuals as well as in their
healthy oﬀspring [19–21].
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Since monitoring of serological parameters typically
involves invasive techniques with associated pain and dis-
tress, eﬀorts are directed at identifying noninvasive mea-
sures for frequent monitoring of diabetes. Some of the
alternative methods evaluated include assessing skin auto-
ﬂuorescence for accumulation of advanced glycation end-
products and measuring analytes in exhaled breath, urine, or
saliva [5, 22–24]. Human saliva is a rich reservoir of analytes
consisting of over 3652 proteins and 12,562 peptides and
shares nearly 51% of proteins and 79% of peptides with the
serum proteome and peptidome, respectively [25, 26]. Al-
terations in the salivary ﬂow and composition in diabetes are
well documented [27, 28]. Both glucose and immunoreactive
insulin are increased in saliva and are correlated with plasma
levels in T2DM patients [29–32]. Circulating biomolecules
are thought to reach saliva by either active (e.g., sIgA) or
passive transportation (e.g., steroids) or ultraﬁltration (e.g.,
creatinine) or from crevicular ﬂuid [26, 33]. )e objective of
this study is to compare the salivary levels of two proin-
ﬂammatory adipokines, namely, resistin and visfatin, and
that of the anti-inﬂammatory adipokine ghrelin between
healthy and T2DM individuals.
2. Materials and Methods
2.1. Study Population. All participants were recruited from
patients attending the Indiana University School of Den-
tistry after obtaining informed consent in full accordance
with the Indiana University Institutional Review Board. )e
study population consisted of twenty periodontally healthy
individuals with self-reported T2DM and HbA1c values.
Twenty gender-matched individuals with no known oral or
systemic condition were recruited as control group. It was
estimated that this sample size will be suﬃcient at 80%
power to detect a diﬀerence in means of 0.91, assuming
a common standard deviation of 1 using a two group t-test
with a two-sided signiﬁcance level of 0.05.
2.2. Collection and Processing of Unstimulated Whole Saliva
(UWS). UWS was collected at approximately the same time
of day by the drooling method as described [34, 35]. Brieﬂy,
subjects were asked to refrain from eating or drinking for 2 h
prior to saliva collection. At least 2mL of UWS was collected
by passively drooling into a chilled centrifuge tube for 5–
10min. )e tubes were codiﬁed and transferred on ice to the
laboratory for processing. Each sample was clariﬁed by
centrifuging at 3500 rpm at 4°C for 10min and stored in
Complete™ Protease Inhibitor Cocktail (Roche, Mannheim,
Germany). )e supernatant-clariﬁed saliva was stored at−80°C until further analysis.
2.3. Enzyme-Linked Immunosorbent Assay (ELISA) for
Resistin and Visfatin. All UWS samples were depleted of
amylase and immunoglobulins by incubating serially
with antihuman amylase mAb (1 : 2500, cat. no. ab8944;
Abcam) and protein G beads (Miltenyi Biotec Inc.) at
4°C. Total protein of the precleaned saliva samples was
determined by spectrophotometry and ranged between
1.3 and 7.7mg/mL [36]. Volume equal to 1 µg of total
protein in precleaned UWS was assessed for resistin, vis-
fatin, and ghrelin per using speciﬁc sandwich ELISA kits
(item no. 10007610 81, part no. 579020-96, and part no.
10006306-96, resp.; Bertin Pharma/Cayman Chemical, Ann
Arbor, MI, USA) following manufacturer’s instructions.
)e cytokines TNF-α and IL-6 in saliva were measured
using speciﬁc ELISA kits (BD Biosciences, CA, USA) fol-
lowing the manufacturer’s instructions.
2.4. Statistical Analysis. For all biomarkers, statistical sig-
niﬁcance between the healthy and diabetes cohorts was
determined by two-tailed paired t-tests; p< 0.05 was con-
sidered signiﬁcant.
3. Results
3.1. Clinical Characteristics. )e study cohort consisted of
twenty individuals with self-reported T2DM and twenty
healthy individuals (Table 1). )e average age of T2DM
cohort was 56.5 yrs and that of healthy group was 48 yrs. )e
average HbA1c value of the T2DM group was 5.4± 1.9%.
Since the HbA1c values reported were measured within the
past three months, the range is consistent with the diagnostic
criteria for T2DM [37].
3.2. Salivary Cytokines in T2DM. We observed that the
UWS concentration of IL-6 and TNF-α was not signiﬁcantly
diﬀerent between T2DM and healthy individuals with no
periodontitis (Figure 1). Similar observation of comparable
salivary IL-6 levels between systemically healthy and di-
abetes individuals with healthy periodontium has been re-
ported by others [38].
3.3. Diﬀerential Expressions of Visfatin, Resistin, and Ghrelin
in Diabetic Saliva. We observed that the UWS from T2DM
subjects possessed signiﬁcantly elevated levels of resistin
(9.2± 2.3 ng/mL) and visfatin (80.2± 42.3 ng/mL) as com-
pared to that from control subjects (5.7± 1.3 ng/mL and
46.0± 17.5 ng/mL, resp.) (Figures 2(a) and 2(b)). No signif-
icant diﬀerence was observed in the salivary concentration of
either unacylated (9.2± 4.3 ng/mL and 10.7± 5.6 ng/mL,
resp.) or acylated (2.7± 2.3 ng/mL and 2.2± 1.4 ng/mL,
Table 1: Demographic characteristics, HbA1c, and total salivary
protein content.
Healthy T2DM
Number of
individuals M 10 12
F 10 8
Age (yrs) 48 (range: 42–55) 56.5 (range: 45–58)
% A1C 7.85
Range: 6–12
Salivary protein
(mg/mL) 3.4± 1.6 5.4± 1.9
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resp.) ghrelin between the T2DM and the control group
(Figure 2(c)).
4. Discussion
Escalating global burden of T2DM underscores the need for
multipronged screening strategies for early identiﬁcation of
individuals at high risk [7, 39]. Furthermore, elucidation of
the molecular pathogenesis has shown that the processes
that lead to T2DM are initiated very early with a long lag
phase between the disease onset and the clinical diagnosis
[6]. Many cross-sectional studies have evaluated multiple
serum proteins as predictive biomarkers for T2DM [5, 7, 39].
Potential applications of salivary biomarkers for T2DM
have gained importance with the establishment of shared
characteristics of salivary and serum proteomes [26]. It has
been suggested that the increased basement membrane per-
meability often associated with diabetes is a potential mech-
anism for the increased passage of proteins and metabolites
from the exocrine glands as well as for the enhanced leakage of
serum-derived components into whole saliva [26, 33, 40].
Clinical application of salivary components as potential
biomarkers is likely to be better accepted for molecules that
correlate with the pathological process of T2DM. Consid-
erable evidence suggests that the T2DM is a multifactorial
disease involving dysregulation of various biological path-
ways such as inﬂammation, adipokine signaling, and
incretin signaling [6]. )e prodiabetic eﬀects of the adi-
pokine resistin have been attributed to inhibition of insulin
signaling and a pro-inﬂammatory mechanism that culmi-
nates in β-cell loss [9, 10, 13, 41]. )e adipokine visfatin has
been shown to exhibit glucose-lowering and insulin-
mimicking/insulin-sensitizing eﬀects [9, 10, 12, 13]. Circu-
lating levels of both resistin and visfatin are upregulated in
T2DM [12, 13, 18, 42]. Previously, others have shown
positive correlation between the serum and salivary levels of
these two adipokines [42–44]. Here, we observed that the
salivary resistin and visfatin concentrations are signiﬁcantly
elevated in T2DM. Similar observations of elevated salivary
visfatin and resistin have been reported earlier in chronic
periodontitis and diabetes [42, 43, 45].
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Figure 1: Salivary TNF-α and IL-6 in T2DM: Unstimulated whole
saliva (UWS) was collected from 20 T2DM individuals and 20
healthy individuals. Each UWS sample was depleted of amylase and
immunoglobulins. Precleaned UWS was assessed for TNF-α and
IL-6 using speciﬁc sandwich ELISA kits.
0
2
4
6
8
10
12
Control T2DM
Re
sis
tin
 (n
g/
m
L)
Control
T2DM
∗
(a)
0
10
20
30
40
50
60
70
80
90
100
Control T2DM
V
isf
at
in
 (n
g/
m
L)
Control
T2DM
∗
(b)
Control
T2DM
0
2
4
6
8
10
12
14
Acylated ghrelin Unacylated ghrelin
(n
g/
m
L)
(c)
Figure 2: Salivary resistin, visfatin, and ghrelin in T2DM:
Unstimulated whole saliva (UWS) was collected from 20 T2DM
individuals and 20 healthy individuals. Each UWS sample was
depleted of amylase and immunoglobulins. Precleaned UWS was
assessed for (a) resistin, (b) visfatin, and (c) acylated and unacylated
ghrelin using speciﬁc assay kits. ∗p< 0.05.
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Ghrelin, the orexigenic peptide hormone also aﬀects
glucose metabolism. Circulating levels of ghrelin rise before
and fall after a meal, thereby contributing to appetite and
weight gain [15]. Plasma concentration of ghrelin has been
negatively correlated with insulin resistance [14, 46]. We
observed that the salivary concentration of both acylated and
unacylated ghrelin was lower in T2DM saliva than that in
healthy saliva although the diﬀerence did not reach statistical
signiﬁcance. Others have reported signiﬁcant reductions in
acylated ghrelin in diabetic saliva [47].)e diﬀerence may be
attributed to the time and method of sample collection and
preparation and the method of ghrelin assessment.
5. Conclusions
Population-based long-term studies suggest that the bio-
marker trajectories along the course of T2DM development
diverge over time [48, 49]. )is suggests that repeated
measures of mechanism-based biomarkers will increase the
predictive value of diabetes risk scores. )e noninvasive
nature and the feasibility of frequent sampling for real-time
monitoring are signiﬁcant advantages of saliva over pe-
ripheral blood as specimen for diagnostic/prognostic ap-
plications. In addition to the practical beneﬁts of eliminating
the need for a phlebotomist, reduced transmission of in-
fectious disease by eliminating needle sticks and greater ease
of testing of special populations of patients (e.g., institutional
and children) make the assessment of biomarkers in hu-
man saliva an attractive economic strategy [24, 50]. Ele-
vated salivary resistin and visfatin in saliva that have also
been shown to correlate with serum levels suggest that
the two adipokines could represent potential noninvasive
T2DM biomarkers [41, 43, 44]. However, caution must be
exercised since the type of sample (stimulated/unstimulated;
whole/glandular), circadian variations, and susceptibility to
preprocessing as well as oral health/disease are some of the
confounding parameters that should be addressed in the
biomarker interpretations and implementation [51, 52].
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